Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19) - Image 1

£112.35

Academic Press Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)

Name: Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)
Brand: Academic Press
Price: 112.49 GBP
Availability: InStock

Oncology

Price History & Forecast

Last 79 days • 79 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 79 days • 1 price levels

Days at Price

Price Analysis

Most common price: £112 (79 days, 100.0%)

Price range: £112 - £112

Price levels: 1 different prices over 79 days

Description

Product Description Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Review Presents resistant mechanisms to EGFR inhibitors in EGFR mutant lung cancer, along with therapeutic strategies that are being explored to overcome resistance From the Back Cover Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, and the clinical strategies to identify these mechanisms and implement newer therapeutic strategies to combat resistance to improve patient survival. The book covers resistant mechanisms to EGFR inhibitors in EGFR mutant lung cancer, and therapeutic strategies being explored to overcome resistance. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. It will also discuss current clinical trials of EGFR inhibitors in EGFR mutant lung cancer and explain the methodology of detection of resistant mechanisms in lung cancer clinic. This book is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested to learn about the most recent and promising treatments for lung cancer. About the Author Dr. Faber’s research program includes studying resistance mechanisms to targeted therapies in lung cancer. During his postdoctoral training, he discovered that low expression levels of functional BIM, a pro-apoptotic protein, was sufficient to impart resistance to EGFR inhibitors in EGFR mutant lung cancer through loss of a cell death response. Loss of functional BIM is now part of clinical decision making for EGFR mutant lung cancer patients and combination therapy of EGFR inhibitors with BH3 mimetics to rescue or improve cell death responses are being explored clinically. Dr. Faber’s laboratory more recently linked epithelial-to-mesenchymal related EGFR inhibitor resistance with low levels of BIM, and a deficient cell death response.

Product Specifications

Brand: Academic Press
Format: hardcover
ASIN: 0128228334
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 05 February 2023
Listed Since: 01 February 2020

Barcode

No barcode data available

Academic Press Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

FIGHTING LUNG CANCER THROUGH THE HER FA (Cancer Etiology, Diagnosis and Treatments)

Multi-Drug Resistance in Cancer: 596 (Methods in Molecular Biology, 596)

Multi-Drug Resistance in Cancer: 596 (Methods in Molecular Biology, 596)

Cancer Drug Resistance (Cancer Drug Discovery and Development)

Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management

Cancer Drug Resistance: Overviews and Methods: 1395 (Methods in Molecular Biology, 1395)

Resistance to Targeted ABC Transporters in Cancer: 4 (Resistance to Targeted Anti-Cancer Therapeutics)

Springer - Lung Cancer: Treatment and Research: 170 Book

Drug Resistance in Cancer Cells

Humana Combination Cancer Therapy: Modulators and Potentiators

Targeting Cell Survival Pathways to Enhance Response to Chemotherapy (Volume 3) (Cancer Sensitizing Agents for Chemotherapy, Volume 3)

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance (Volume 12) (Cancer Sensitizing Agents for Chemotherapy, Volume 12)

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)

Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy)

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies (Volume 8) (Cancer Sensitizing Agents for Chemotherapy, Volume 8)

Advances in Respiratory Cancerogenesis: 911 (Advances in Experimental Medicine and Biology, 911)

Breast Cancer Metastasis and Drug Resistance: Challenges and Progress: 1152 (Advances in Experimental Medicine and Biology, 1152)

Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)

Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17)

Humana PI3K-mTOR in Cancer and Cancer Therapy Book

Molecular and Clinical Advances in Anticancer Drug Resistance: 57 (Cancer Treatment and Research, 57)

Cancer Cell Chemoresistance And Chemosensitization

Cytotoxic Drug Resistance Mechanisms: 28 (Methods in Molecular Medicine, 28)